Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $57.30

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $61.30.

Several analysts have weighed in on the stock. Guggenheim boosted their price target on shares of AnaptysBio from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday. UBS Group reiterated a “neutral” rating and issued a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. HC Wainwright increased their target price on AnaptysBio from $38.00 to $59.00 and gave the stock a “buy” rating in a research report on Tuesday, September 30th. JPMorgan Chase & Co. increased their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Finally, Stifel Nicolaus lifted their price objective on AnaptysBio from $55.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $38.20 on Friday. The company has a fifty day moving average of $28.43 and a 200-day moving average of $24.55. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $40.96. The company has a market capitalization of $1.06 billion, a P/E ratio of -13.55 and a beta of 0.16.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The firm had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. As a group, analysts forecast that AnaptysBio will post -6.08 EPS for the current fiscal year.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently modified their holdings of ANAB. BIT Capital GmbH bought a new stake in AnaptysBio during the 1st quarter valued at approximately $473,000. HighMark Wealth Management LLC raised its position in shares of AnaptysBio by 58.2% during the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock valued at $3,231,000 after buying an additional 53,550 shares during the last quarter. Nuveen LLC purchased a new position in shares of AnaptysBio in the first quarter worth $1,041,000. First Light Asset Management LLC boosted its position in shares of AnaptysBio by 433.3% during the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock worth $86,139,000 after acquiring an additional 3,764,720 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ purchased a new position in AnaptysBio during the first quarter valued at $623,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.